
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2073887/publications.pdf Version: 2024-02-01



Ορι Εικαναμ

#	Article	IF	CITATIONS
1	2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases, 2020, 79, 39-52.	0.9	506
2	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the Rheumatic Diseases, 2021, 80, 1330-1338.	0.9	503
3	Immunogenicity and Safety of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus. Clinical Infectious Diseases, 2002, 34, 147-153.	5.8	172
4	The Effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Seminars in Arthritis and Rheumatism, 2004, 33, 283-288.	3.4	160
5	The Effect of Infliximab and Timing of Vaccination on the Humoral Response to Influenza Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Seminars in Arthritis and Rheumatism, 2010, 39, 442-447.	3.4	122
6	Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology, 2021, 60, SI90-SI95.	1.9	122
7	Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis and Rheumatism, 2002, 46, 2571-2573.	6.7	121
8	Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open, 2019, 5, e001035.	3.8	113
9	Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open, 2019, 5, e001041.	3.8	104
10	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the Rheumatic Diseases, 2022, 81, 1628-1639.	0.9	89
11	The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. Journal of Rheumatology, 2016, 43, 1749-1754.	2.0	85
12	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). Annals of the Rheumatic Diseases, 2017, 76, 203-207.	0.9	78
13	Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care and Research, 2011, 63, 1062-1067.	3.4	76
14	Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA - Journal of the American Medical Association, 2022, 327, 341.	7.4	76
15	Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases. RMD Open, 2021, 7, e001594.	3.8	59
16	Pneumococcal vaccination of patients with systemic lupus erythematosus: Effects on generation of autoantibodies. Autoimmunity, 2005, 38, 493-496.	2.6	49
17	Tocilizumab in Adult-onset Still's Disease: the Israeli Experience. Journal of Rheumatology, 2014, 41, 244-247.	2.0	46
18	Prevalence of TNF-α Blocker Immunogenicity in Psoriatic Arthritis. Journal of Rheumatology, 2015, 42, 73-78.	2.0	46

#	Article	IF	CITATIONS
19	Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts. Cytokine, 2015, 73, 30-35.	3.2	43
20	ls treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 2020, 79, 453-459.	0.9	43
21	Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases. Autoimmunity Reviews, 2007, 6, 312-314.	5.8	41
22	Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity, 2005, 38, 155-160.	2.6	32
23	The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis. European Journal of Clinical Investigation, 2020, 50, e13268.	3.4	31
24	Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis. Rheumatology International, 2004, 24, 93-97.	3.0	30
25	Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology, 2022, 61, 4263-4272.	1.9	29
26	Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders. Rambam Maimonides Medical Journal, 2016, 7, e0012.	1.0	28
27	Self-Reported Childhood Maltreatment and Traumatic Events among Israeli Patients Suffering from Fibromyalgia and Rheumatoid Arthritis. Pain Research and Management, 2017, 2017, 1-8.	1.8	26
28	The Effect of Pregnancy on Disease Activity in Patients with Psoriatic Arthritis. Journal of Rheumatology, 2018, 45, 1651-1655.	2.0	26
29	Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab. Vaccine, 2020, 38, 847-851.	3.8	26
30	Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. Journal of Rheumatology, 2016, 43, 267-272.	2.0	25
31	Safety and Efficacy of Vaccination Against Influenza in Patients With Rheumatoid Arthritis. Clinical and Developmental Immunology, 2006, 13, 349-351.	3.3	24
32	The effect of anti-tuberculosis treatment on levels of anti-phospholipid and anti-neutrophil cytoplasmatic antibodies in patients with active tuberculosis. Rheumatology International, 2013, 33, 949-953.	3.0	24
33	Magnetic resonance imaging in diffuse idiopathic skeletal hyperostosis: similarities to axial spondyloarthritis. Clinical Rheumatology, 2017, 36, 1545-1549.	2.2	24
34	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2023, 82, 65-73.	0.9	24
35	The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment. Arthritis Research and Therapy, 2010, 12, R12.	3.5	23
36	Cocaine-induced Vasculitis. Rambam Maimonides Medical Journal, 2016, 7, e0036.	1.0	23

#	Article	IF	CITATIONS
37	The Diagnosis and Treatment of Adult Patients with SAPHO Syndrome: Controversies Revealed in a Multidisciplinary International Survey of Physicians. Rheumatology and Therapy, 2020, 7, 883-891.	2.3	21
38	Biologic registries in rheumatology: Lessons learned and expectations for the future. Autoimmunity Reviews, 2012, 12, 329-336.	5.8	18
39	Prevalence of Axial Spondyloarthritis Among Patients With Fibromyalgia: A Magnetic Resonance Imaging Study With Application of the Assessment of SpondyloArthritis International Society Classification Criteria. Arthritis Care and Research, 2017, 69, 724-729.	3.4	17
40	Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis. Clinical and Experimental Rheumatology, 2015, 33, 181-6.	0.8	17
41	Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease. Rheumatology International, 2001, 20, 43-47.	3.0	15
42	Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Therapeutics and Clinical Risk Management, 2015, 11, 1719.	2.0	14
43	Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients. Pain Research and Management, 2018, 2018, 1-4.	1.8	14
44	Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology, 2018, 57, 1472-1480.	1.9	14
45	The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature. Life, 2021, 11, 258.	2.4	14
46	Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia. Annals of the Rheumatic Diseases, 2021, 80, 1553-1558.	0.9	13
47	Good pain, bad pain: illness perception and physician attitudes towards rheumatoid arthritis and fibromyalgia patients. Clinical and Experimental Rheumatology, 2021, 39, 54-60.	0.8	12
48	The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients. Clinical Microbiology and Infection, 2022, 28, 735.e5-735.e8.	6.0	12
49	Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate. Clinical Rheumatology, 2016, 35, 363-370.	2.2	11
50	Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 1577-1581.	2.0	11
51	Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice. European Journal of Rheumatology, 2019, 6, 136-141.	0.6	11
52	A novel approach for knee osteoarthritis using high molecular weight hyaluronic acid conjugated to plasma fibrinogen – interim findings of a double-blind clinical study. Heliyon, 2020, 6, e04475.	3.2	10
53	Soluble ST2 and CXCL-10 may serve as biomarkers of subclinical diastolic dysfunction in SLE and correlate with disease activity and damage. Lupus, 2020, 29, 1430-1437.	1.6	10
54	Lymphocyte activation gene-3 (LAG-3) regulatory T cells: An evolving biomarker for treatment response in autoimmune diseases. Autoimmunity Reviews, 2022, 21, 103085.	5.8	9

#	Article	IF	CITATIONS
55	The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients. Clinical Immunology, 2018, 192, 85-91.	3.2	8
56	Bilateral Neuroretinitis and a Unilateral Superior Hemivein Occlusion with Frosted Branch Angiitis Pattern Presenting Simultaneously in BehA§et's Disease. Case Reports in Ophthalmology, 2016, 7, 141-147.	0.7	6
57	CD4+LAG-3+ T cells are decreased in active psoriatic arthritis patients and their restoration <i>in vitro</i> is mediated by TNF inhibitors. Clinical and Experimental Immunology, 2021, 206, 173-183.	2.6	5
58	Prevalence of Nonradiographic Sacroiliitis in Patients With Psoriatic Arthritis: A Real-life Observational Study. Journal of Rheumatology, 2021, 48, 1014-1021.	2.0	5
59	Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. Biologics: Targets and Therapy, 2021, Volume 15, 463-470.	3.2	5
60	Relationship between religiosity, spirituality and physical and mental outcomes in fibromyalgia patients. Clinical and Experimental Rheumatology, 2021, 39, 48-53.	0.8	5
61	Familial Erythema Nodosum. Arthritis and Rheumatism, 1991, 34, 1177-1179.	6.7	4
62	Ultrasound, magnetic resonance imaging and radiography of the finger joints in psoriatic arthritis patients. Rheumatology, 2022, 61, 563-571.	1.9	4
63	T cell functions of psoriatic arthritis patients are regulated differently by TNF, IL-17A and IL-6 receptor blockades in vitro. Clinical and Experimental Rheumatology, 2022, 40, 120-128.	0.8	4
64	Abdominal scintigraphy using technetium Tc 99m hexylmethylpropylene amine oxime–labeled leukocytes in patients with seronegative spondyloarthropathies. Seminars in Arthritis and Rheumatism, 2002, 31, 406-412.	3.4	3
65	Prevalence of high-sensitivity cardiac troponin T in real-life cohorts of psoriatic arthritis and general population: a cross-sectional study. Rheumatology International, 2020, 40, 437-444.	3.0	3
66	Pustular Psoriasis and Associated Musculoskeletal Disorders. Journal of Rheumatology, 2021, , jrheum.201673.	2.0	3
67	Comment on: Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series: reply. Rheumatology, 2021, 61, e30-e30.	1.9	3
68	Sputum Anticitrullinated Protein Antibodies in Patients With Long-standing Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2018, 24, 122-126.	0.9	2
69	Susac's syndrome – A new ocular finding and disease outcome. Eye, 2022, 36, 781-788.	2.1	2
70	Prevalence of COVID â€19 and seroprevalence to SARSâ€CoV â€2 in a rheumatologic patient population from a tertiary referral clinic in Israel. Internal Medicine Journal, 2021, 51, 682-690.	0.8	2
71	High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis. Biologics: Targets and Therapy, 2021, Volume 15, 279-287.	3.2	2
72	Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials. Journal of Vestibular Research: Equilibrium and Orientation, 2020, 30, 393-399.	2.0	2

#	Article	IF	CITATIONS
73	Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System. Israel Medical Association Journal, 2016, 18, 630-632.	0.1	2
74	Clinical Images: Marked Inflammation in a Patient with Cervical Vertebral SAPHO Complicated by Vertebral Body Collapse and Severe Kyphosis. Israel Medical Association Journal, 2017, 19, 725-726.	0.1	2
75	Evaluating IBD-specific antiglycan antibodies in serum of patients with spondyloarthritis and rheumatoid arthritis: are they really specific?. Clinical and Experimental Rheumatology, 2019, 37, 32-36.	0.8	2
76	Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases. Clinical and Experimental Rheumatology, 0, , .	0.8	2
77	Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis. Clinical and Experimental Rheumatology, 2022, 40, 15-23.	0.8	2
78	Good pain, bad pain: illness perception and physician attitudes towards rheumatoid arthritis and fibromyalgia patients. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 54-60.	0.8	1
79	Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
80	T cell functions of psoriatic arthritis patients are regulated differently by TNF, IL-17A and IL-6 receptor blockades in vitro. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
81	Seroprevalence of SARS-CoV-2 antibodies in patients with autoimmune inflammatory rheumatic diseases. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
82	P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Rheumatology, 2022, 61, .	1.9	1
83	Expression levels of selected genes can predict individual rheumatoid arthritis patient response to tumor necrosis factor alpha blocker treatment. Current Medical Research and Opinion, 2018, 34, 1777-1783.	1.9	0
84	Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials. Journal of Vestibular Research: Equilibrium and Orientation, 2020, , 1-7.	2.0	0
85	Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine, 2020, 382, 1666-1668.	27.0	0
86	Paraneoplastic Dactylitis Leading to the Diagnosis of Ovarian Cancer. Israel Medical Association Journal, 2019, 21, 354-355.	0.1	0
87	A Study of the Efficacy and Safety of Subcutaneous Injections of Tocilizumab in Adults with Rheumatoid Arthritis. Israel Medical Association Journal, 2020, 22, 557-563.	0.1	0
88	Real-world effectiveness of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clinical and Experimental Rheumatology, 2021, 39, 1378-1384.	0.8	0
89	Relationship between religiosity, spirituality and physical and mental outcomes in fibromyalgia patients. Clinical and Experimental Rheumatology, 2021, 39 Suppl 130, 48-53.	0.8	0